Figure 1. Allelic balance ratios for squamous cell carcinoma (SCC) in immunocompetent patients (ICPs) and organ transplant recipients (OTRs). A, Allelic balance was similarly reduced in all SCC (intraepithelial and invasive) samples. Two-tailed P values were determined with Wilcoxon matched-pairs test. Total number of patients, 80. IFNA informative paired samples, 20 (P = .56); D9S162 informative paired samples, 29 (P = .47); and D9S925 informative paired samples, 31 (P = .58). B, Squamous cell carcinoma in OTRs overall showed reduced allelic balance for D9S162 vs SCC in ICPs. Two-tailed P values were determined with the Mann-Whitney test. Total number of SCC samples, 170. IFNA informative samples: ICPs, 42; OTRs, 31 (P = .35). D9S162 informative samples: ICP, 49; OTRs, 37 (P = .04). D9S925 informative samples: ICPs, 49; OTRs, 46 (P = .21). Two-tailed P values were determined with Wilcoxon matched-pairs test. The horizontal line in the middle of each box indicates the median, while the top and bottom borders of the box mark the 75th and 25th percentiles. The whiskers represent the 95th and 9th percentiles.
Figure 2. Allelic balance ratios in actinic keratosis (AK) and Bowen disease (BD). A, Overall, AK showed reduced allelic balance for D9S162 compared with BD. Bowen disease showed significantly higher allelic balance at D9S162 compared with AK (P = .004). IFNA informative samples: AK, 30; BD, 10. D9S162 informative samples: AK, 32; BD, 11. D9S925 informative samples: AK, 31; BD, 14. Two-tailed P values were determined with the Mann-Whitney test. Total number of AK, 63; BD, 22. B, Actinic keratosis in organ transplant recipients (OTRs) showed less allelic balance for D9S162 than BD in OTRs (P = .01; Mann-Whitney test). IFNA informative samples: AK, 12; BD, 5. D9S162 informative samples: AK, 13; BD, 7. D9S925 informative samples: AK, 13; BD, 10. Total number of intraepithelial squamous cell carcinoma (SCC) samples in OTRs: AK, 29; BD, 13. P values were determined with the Fisher exact test. The box and whisker plot elements are defined in the legend to Figure 1. C, AK in OTRs expressed less p16 protein than did BD in OTRs (P < .005; analysis of variance). The numbers on the x-axis represent the proportion of p16 immunoreactive tumor cells grouped by percentage of immunoreactive cells within the tumors. ICPs indicates immunocompetent patients; NS, nonsignificant.
Figure 3. Allelic balance ratios of invasive squamous cell carcinoma (SCC) in immunocompetent patients (ICPs) and organ transplant recipients (OTRs). A, Invasive SCC in OTRs shows reduced allelic balance for D9S162 compared with invasive SCC in ICPs (P = .048; 2-tailed P value was determined with the Mann-Whitney test). IFNA informative samples: ICPs, 19; OTRs, 14. D9S162 informative samples: ICPs, 26; OTRs, 17. D9S925 informative samples: ICPs, 27; OTRs, 23. Total number of invasive SCC samples, 85. The box and whisker plot elements are defined in the legend to Figure 1. B, Invasive SCC of OTRs expressed more p16 protein than invasive SCC of immunocompetent patients (P < .001; analysis of variance). The numbers on the x-axis represent the proportions of p16 immunoreactive tumor cells in intraepithelial and invasive SCC in ICPs and OTRs grouped by the percentage of immunoreactive cells within the tumors.
Mühleisen B, Petrov I, Frigerio S, Dziunycz S, French LE, Hofbauer GFL. Pronounced allelic
imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients. Arch
Dermatol. Published online April 16, 2012. doi:10.1001/archdermatol.2012.107.
Exemplary characterization of allelic balance at the 3 microsatellite loci IFNA,
D9S162 and D9S925 on chromosome 9p
eFigure 2. Exemplary p16 protein expression (upper half) in cutaneous squamous cell
carcinoma detected by immunohistochemistry
eTable. Characteristics of microsatellites in this study
Mühleisen B, Petrov I, Frigerio S, Dziunycz P, French LE, Hofbauer GFL. Pronounced Allelic Imbalance at D9S162 in Skin Squamous Cell Carcinoma of Organ Transplant Recipients. Arch Dermatol. 2012;148(6):697-703. doi:10.1001/archdermatol.2012.107
Author Affiliations: Department of Dermatology (Drs Mühleisen, Dziunycz, French, and Hofbauer) and Institute of Surgical Pathology (Dr Frigerio), University Hospital Zurich, Zurich, Switzerland; and Department of Dermatology, Tokuda Hospital, Sofia, Bulgaria (Dr Petrov).
Objective To evaluate chromosomal instability at 9p21-22 with p16 protein expression in organ transplant recipients (OTRs) compared with immunocompetent patients with squamous cell carcinoma (SCC).
Design In a select population of intraepithelial and subsequent invasive SCC from the same anatomic region of the same patient at different times, we assessed loss of heterozygosity at 3 microsatellites—IFNA, D9S162, and D9S925—in the course of carcinogenesis in OTRs and immunocompetent patients.
Setting Department of Dermatology, University Hospital Zurich.
Patients Immunocompetent patients and OTRs with SCC on sun-damaged skin.
Main Outcome Measure Chromosomal allelic balance in SCC of OTRs and immunocompetent patients.
Results Reduced allelic balance at IFNA, D9S162, and D9S925 in intraepithelial forms of SCC and similar allelic imbalance in invasive forms of SCC were found. Allelic balance at D9S162 was reduced for SCC in OTRs compared with SCC in immunocompetent patients. The study revealed broadly reduced allelic balance at 9p21-22 in all cutaneous SCCs, and OTRs presented a further reduced allelic balance for D9S162, suggesting a common trait for SCC in OTRs. Actinic keratosis and Bowen disease differed in allelic balance at D9S162, suggesting substantial differences in their carcinogenesis.
Conclusion Reduced allelic balance around locus D9S162 is a genomic correlate for enhanced carcinogenesis in OTRs.
Squamous cell carcinoma (SCC) of the skin is a common cutaneous malignant neoplasm of keratinocytes and occurs most often in white individuals. In the setting of chronic immunosuppression, such as in organ transplant recipients (OTRs), the incidence of SCC rises dramatically, by 65- to 100-fold, compared with the general population.1 Chronic UV damage is a major risk factor and results in keratinocyte DNA damage, both initiating and propagating SCC formation. Intraepithelial lesions such as actinic keratosis (AK) and Bowen disease (BD) are increasingly considered in situ SCC.2,3
The occurrence of SCC is not an isolated event; rather, it indicates field cancerization, ie, the presence of widespread DNA damage in the keratinocytes of sun-exposed skin, which continues to cause intraepithelial and invasive SCC in affected patients.4 Genomic instability is a hallmark of many different neoplasias. The resultant allelic imbalance, that is, loss of heterozygosity (LOH), at particular loci can be used as a marker for an ongoing neoplastic process. Mutations on chromosome arm 9p have been described5- 9 in a variety of tumors. In one SCC study,10 LOH encompassing 9p21-22 occurred in 41% of the tumors. Rehman and coworkers11 found 20% of AK with LOH of 8 or more alleles, 39% of which were on chromosome arm 9p.
Cyclin-dependent kinase inhibitor p16INK4 specifically inhibits progression through the G1 phase of the cell cycle by blocking the cyclin-dependent kinase 4 from phosphorylating the retinoblastoma protein.12 Loss of heterozygosity, as well as loss of parts or the entire short arm of chromosome arm 9, where p16INK4 maps to 9p21, is frequently observed in SCC.13,14 Nilsson et al15 found weak and cytoplasmic p16INK4 expression in AK, strong nuclear and cytoplasmic p16INK4 expression in carcinomas in situ (BD), and variable p16INK4 expression in invasive SCC. Blokx and colleagues16 assessed p16 and p53 protein expression in 23 AK (termed low-grade keratinocytic intraepidermal neoplasia [KIN]), 28 BD (high-grade KIN), and 35 invasive SCCs from 44 OTRs and 42 immunocompetent patients, concluding that p16 expression was independent of immune status and of p53 expression. Other tumor suppressor genes located in the 9p21-22 region include INK4b and ARF (alternative reading frame).17- 19
The aim of this study was to determine the imprint of field cancerization in the course of carcinogenesis in a highly select population of intraepithelial and subsequently invasive SCC from the same anatomic region of the same patient at different times. Allelic imbalance on 9p21-22 as a well-known highly variable region in SCC was analyzed. Because OTRs empirically show a greatly increased incidence of SCC and are known to harbor genetic damage in addition to that which is generally incurred by UV damage alone,20,21 SCC of both immunocompetent patients and OTRs were included.
The use of clinically indicated biopsy material for the study was approved by the ethical committee of the Canton of Zurich, Switzerland. All experiments were performed at the Departments of Dermatology and Pathology, University Hospital Zurich.
The goal of this study was to obtain tissue material from an area of field cancerization that had first given rise to an intraepithelial SCC and at least 1 year later to an invasive SCC of the skin. Paraffin-embedded archival tissue specimens from 43 immunocompetent patients and 42 immunosuppressed OTRs were randomly selected. All the participants first had an intraepithelial form of cutaneous SCC, such as AK or BD, followed by an invasive SCC of the skin in the same anatomic region at least 1 year later. These intraepithelial forms were then compared with the subsequent invasive SCC in the same individual. Of the 42 organ transplants, 32 were kidney, 4 were lung, and 6 were heart (Table 1). All tumors were located on chronically sun-exposed skin of the head, neck, and upper extremities. The histologic diagnosis was made by a board-certified dermatopathologist on the basis of criteria defined by the World Health Organization classification of skin tumors.22 Actinic keratoses and BD samples were analyzed separately and compared with each other and then were grouped as intraepithelial SCC to compare them with invasive SCC.
From each sample, 3 to 5 adjacent slices of 10-μm thickness were stained with hematoxylin-eosin. Microdissection was performed under a light microscope (magnification ×400). In each sample, 150 tumor cells were selectively removed using a disposable 30-gauge needle. In addition, 150 normal skin cells (apocrine glands and endothelial cells far from the tumor) were harvested from the same slides and served as internal controls.
Microdissected cells were immediately suspended in 20 μL of digestion solution containing 50mM TRIS-HCl, 1mM EDTA, 1% Tween 20, and 2.5 mg/mL of proteinase K (pH 8.0, P2308; Sigma-Aldrich, Inc) and incubated for 16 hours at 37°C. The mixture was then heated for 10 minutes at 94°C to inactivate proteinase K. Five microliters of this solution was used as the template DNA for polymerase chain reaction (PCR) amplification.
To establish a highly reproducible LOH analysis for cutaneous SCC, 3 microsatellite marker loci on chromosome arm 9 (IFNA, D9S925, and D9S162), previously linked to early tumor development23 and flanking the p16 tumor suppressor gene region, were selected. These loci included either dinucleotide or tetranucleotide tandem repeats known for their high degree of allelic variability and, hence, useful source of information (Table 2). Polymerase chain reaction of the 3 different microsatellite markers was performed with separate primer pairs, of which 1 oligonucleotide was labeled at the 5′ sense strand end with the fluorescent dyes 6-FAM, HEX (Microsynth), or NED (Applied Biosystems). The primer sequences were as follows: IFNA up: GTAAGGTGGAAACCCCC (FAM); IFNA low: TGCGCGTTAAGTTAATTGG; D9S162 up: CCAGAGAAACAGAACCA (NED); D9S162 low: ACAACAAATCTCCTCACA; D9S925 up: TGTGAGCCAAGGCCTTATAG (HEX); and D9S925 low: GTCTGGGTTCTCCAAAGAAA. Amplification of specific DNA was performed in a reaction volume of 25 μL including 0.2mM dNTPs (deoxynucleotide triphosphates) (Roche Diagnostics), 2.5mM magnesium chloride, and 0.5 U of a DNA polymerase (AmpliTaq Gold; both from Applied Biosystems). Cycling was performed (GeneAmp PCR System 9700; Applied Biosystems) using the following temperature conditions: 94°C for 1 minute, 55°C for 1 minute, 72°C for 2 minutes for 40 cycles, and a final extension for 60 minutes at 60°C. The PCR products were subsequently denatured for 1 minute at 95°C (Hi-Di formamide; Applied Biosystems) and separated on a genetic analyzer (ABI PRISM 3100; Applied Biosystems) equipped with a 36-cm capillary array loaded with performance-optimized polymer 4 (POP-4; Applied Biosystems); ROX-400HD was used as an internal size standard (Applied Biosystems). Artifacts generally can be a concern in LOH analysis. Polymerase chain reaction for each locus was performed twice with similar results. Moreover, several samples were analyzed, which allows for statistical assurance of true allelic imbalance.
Analysis of the samples was carried out using commercial software (GeneMapper, version 3.7; Applied Biosystems). A case was considered informative for a polymorphic marker if normal tissue DNA showed 2 different alleles. To identify samples with LOH, the allelic balance ratios of heterozygous markers from the cutaneous SCC DNA and from the patient's control DNA (from normal skin cells) were compared. Briefly, the ratio of the peak areas of the 2 alleles amplified from the tumor sample was divided by the peak areas of the 2 alleles from the control DNA. When the result of this calculation exceeded 1, the reciprocal value was used. Consequently, the calculated numbers varied between 0 (representing complete LOH) and 1 (retained heterozygosity) (eFigure 1). To determine whether the allelic imbalance ratio in a tumor sample met the criterion for LOH, published standard threshold values for these 3 loci were applied.24
We used 3- to 5-μm adjacent sections for hematoxylin-eosin staining and immunohistochemistry. The deparaffinized sections were heated in a 100-W household microwave oven at maximum power 3 times at 5 minutes each in 10mM citric acid for antigen retrieval. Primary antibody was then applied for 60 minutes at room temperature. Immunohistochemical staining was performed with monoclonal IgG mouse antibodies specifically binding human p16INK4 (1:200, G175-405, 550834; PharMingen) and p53 (1:100, DO-7, Pab 1801; Sigma Biosciences). Secondary staining was performed using the alkaline phosphatase antialkaline phosphatase method.25 Normal epidermis and dermal cells served as internal negative controls. Sections of benign melanocytic nevi and breast cancer tissue served as external positive controls. Immunoreactivity was rated as 0% to 5%, 6% to 25%, 26% to 50%, 51% to 75%, and 76% to 100% positive tumor cells. Personnel reviewing the samples were unaware of the patients' diagnosis and immune status. For exemplary staining of p16 and p53, see eFigure 2.
Allelic balance ratios and immunoreactivity between 2 independent groups were calculated using the Mann-Whitney test, and frequencies of LOH between the 2 groups were evaluated using the Fisher exact test. Correlations between LOH, p16, and p53 were expressed using Spearman rank correlation (ρ). Statistical significance was set at P < .05. Statistical analyses were performed using commercial software (SPSS for Windows 11.5, SPSS Inc; GraphPad Prism 5.0, GraphPad Software Inc; and Microsoft Excel 2000, Microsoft Corp).
Considerably reduced allelic balance was found on microsatellite loci IFNA, D9S162, and D9S925 on chromosome arm 9p and was similar in intraepithelial and invasive SCC. Median allelic balance in all tumors was 0.80 for IFNA (n = 73), 0.76 for D9S162 (n = 86), and 0.75 for D9S925 (n = 95) (mean, 0.73, 0.69, and 0.71, respectively). At all 3 loci, there was no significant reduction in allelic balance on the course from intraepithelial to invasive SCC (IFNA, 0.79 for intraepithelial SCC and 0.80 for invasive SCC [n = 20], P = .56; D9S162, 0.72 and 0.77 [n = 29], P = .47; and D9S925, 0.80 and 0.73 [n = 31], P = .58; Wilcoxon matched-pair test, 2-tailed P values) (Figure 1A). Loss of heterozygosity, defined as allelic balance below threshold values for these 3 loci (eTable 1), was found in 61.6% of informative samples at locus IFNA, in 41.9% at D9S162, and in 50.5% at D9S925. Loss of heterozygosity was frequent already in intraepithelial SCC (IFNA, 60.0%; D9S162, 39.5%; and D9S925, 40.0%) and did not increase significantly on the course to invasive SCC (63.6%, 44.2%, and 60.0%, respectively; data not shown).
The analysis detected reduced allelic balance at D9S162 in OTRs compared with immunocompetent patients with SCC (0.70 [n = 37] vs 0.76 [n = 49]; P = .04) (Figure 1B). Allelic balance at IFNA and D9S925 was similar between immunocompetent patients and OTRs (P = .12 and P = .98, respectively). Loss of heterozygosity as defined by threshold values (eTable ) was more frequent at D9S162 in OTRs than in immunocompetent patients (34.8% vs 45.0% of informative samples; P = .04) but similar at IFNA and D9S925 (data not shown).
Actinic keratosis showed reduced allelic balance at D9S162 compared with BD. Allelic balance for all samples of AK together was reduced at D9S162 (0.69) in contrast to BD (0.84; P = .004). At IFNA and D9S925, AK and BD showed similar allelic balance (0.83 vs 0.75 and 0.84 vs 0.79, respectively) (Figure 2A). Loss of heterozygosity as defined by the respective threshold values was significantly less frequent in BD at D9S162 than in AK (50.0% vs 10.0%; P = .03) (data not shown).
Subgroup analysis in OTRs revealed that the allelic difference observed for AK and BD overall stems mainly from malignant neoplasms in OTRs: the allelic balance at D9S162 was higher in BD than in AK (0.93 [n = 10] vs 0.61 [n = 13]; P = .01) (Figure 2B). In the immunocompetent subgroup, there was no significant difference between AK and BD at D9S162 (P = .09; data not shown). Intraepithelial SCC overall did not differ significantly between OTRs and immunocompetent patients in allelic balance at any of the 3 loci (data not shown).
The p16 immunoreactive tumor cells were found in a higher proportion in BD (22 samples) than in AK (63 samples) (P < .001 for all BD vs AK). This was primarily the result of an expression difference in OTR intraepithelial SCC (BD, 13 samples; AK, 29 samples; P < .001 [Figure 2C]), whereas p16 expression did not differ significantly between BD and AK in immunocompetent patients (data not shown).
The difference in allelic balance found for D9S162 in combined SCC samples from OTRs and immunocompetent patients primarily occurred in the invasive SCC subgroup. In invasive SCC, allelic balance at D9S162 was reduced in OTRs (0.62 [n = 17]) compared with immunocompetent patients (0.82 [n = 26]; P = .048) (Figure 3A).
There was a higher proportion of p16 immunoreactive tumor cells in invasive SCC in OTRs than in immunocompetent patients. In all SCC samples, p16 protein expression was upregulated compared with normal skin and similar between immunocompetent patients and OTRs (P = .23; data not shown). Subgroup analysis of invasive SCC, however, revealed higher proportions of p16 immunoreactive tumor cells in OTRs than in immunocompetent patients (P < .001, Figure 3B).
Protein expression of p16 and p53 did not correlate with allelic balance at IFNA, D9S162, or D9S925. Because the gene locus for p16 is flanked by microsatellite loci IFNA and D9S162, the correlation between p16 immunoreactivity and allelic imbalance at the 3 microsatellite markers was assessed. Protein expression of p16 did not correlate with allelic balance at the 3 loci (IFNA, ρ = 0.086; D9S162, ρ = 0.056; and D9S925, ρ = 0.131) (Table 2). Expression of p53, which was determined as a tumor suppressor protein not coded on 9p21-22 and frequently upregulated in SCC, was upregulated in all SCC samples to a similar degree without significant differences (data not shown). Protein expression of p53 also did not correlate with allelic balance at the 3 loci (IFNA, ρ = −0.001; D9S162, ρ = 0.105; and D9S925, ρ = −0.132) (Table 2). Previous analysis of human papillomavirus protein expression by immunohistochemistry in these samples also found this expression to be very low.26
A highly selected SCC sample group was analyzed. All samples were paired from the same patient and the same anatomic region, first with an intraepithelial sample and at least 1 year later with an invasive SCC sample. Such careful selection allows closer observation of allelic imbalance during SCC development, particularly in the transition of SCC across the dermoepidermal junction, and may yield meaningful insight with a limited number of samples.26,27
The analyzed region of the chromosome arm 9p21-22 is a well-known, highly variable region in SCC of different organs. One of the genes located in this region is cyclin-dependent kinase inhibitor p16INK4. The p16 protein specifically inhibits progression through the G1 phase of the cell cycle by blocking the cyclin-dependent kinase 4 from phosphorylating the retinoblastoma protein. Thus, this gene may play the role of an antioncogene. We aimed to study the allelic imbalance and putative consequence in p16 protein expression levels. Our study shows a difference in allelic imbalance at 9p21-22 and p16INK4 expression between AK and BD, which suggests a role of this particular chromosomal locus for SCC carcinogenesis.
The chromosomal region 9p21-22 in our SCC samples was broadly impaired in its allelic balance, a common finding for all samples assessed. These findings are in line with previously published5- 11 data on SCC and other malignant neoplasms. Rehman and coworkers11 found that 20% of AK samples showed LOH of 8 or more alleles, with 39% from 9p. In a study on LOH in SCC, Quinn and colleagues10 found LOH in a distinct region encompassing 9p21-22 to occur in 41% of the samples. This led to the hypothesis that the tumor suppressor gene CDKN2A may play a critical role in SCC development. Mutational analysis and loss of transcript expression further suggests that inactivation of CDKN2A is important for SCC progression.28- 31 In contrast to basal cell carcinoma, the pattern and degree of LOH in SCC were more diverse and widespread. This suggests that increased allelic imbalance on 9p21-22 in early lesions, such as AK and BD, supports the notion that AK, BD, and invasive SCC are part of the same continuum of SCC2,32 and that DNA damage at 9p21-22 may be an early event in the carcinogenesis of SCC.
The marker D9S162 in particular showed a loss of allelic balance that distinguished SCC in OTRs from SCC in immunocompetent patients and was the most varied in all comparisons made. Not only did SCC in OTRs show a reduced allelic balance for this marker, but allelic balance of D9S162 distinguished AK from BD for all intraepithelial lesions, with OTRs contributing primarily to this difference. Invasive SCC again showed allelic balance of D9S162 to be reduced in OTRs compared with immunocompetent patients. Increased and particular patterns of DNA damage have been reported1,21 in OTRs and ascribed to, for example, the effect of azathioprine. Azathioprine is an antimetabolite that doubles photosensitivity to UV-A in keratinocytes and enables direct DNA damage by UV-A.20Although the underlying factors cannot be differentiated in the studied samples, these results may suggest that pronounced loss of allelic balance for D9S162 seems particular to SCC in OTRs compared with SCC in the general immunocompetent population.
Actinic keratosis was initially grouped with BD as intraepithelial SCC for our analysis. Allelic balance on 9p21-22, however, differed greatly between these 2 conditions, showing a clear reduction of allelic balance for AK compared with BD. This suggests that BD may be set apart in its early mutational steps from the continuum of AK and invasive SCC. The gene locus for p16 is flanked by microsatellite loci IFNA and D9S162; thus, allelic imbalance in these markers may affect expression of this tumor suppressor protein. Indeed, AK showed a lower expression of p16 by immunohistochemistry. As for allelic imbalance, the expression difference for p16 was mainly found within intraepithelial lesions of OTRs. Two immunohistochemical studies evaluating p16INK4 expression in AK, BD, and SCC of the skin presented rather controversial results. Hodges and Smoller33 found immunoreactivity in nearly all patients with AK and BD but only in 30% of those with invasive SCC, whereas Salama and colleagues34 showed a high frequency of immunoreactivity for BD but very little for AK and none for SCC. From this, Salama et al concluded that p16INK4 is a selective and specific marker to distinguish BD from SCC. The present study shows that AK in OTRs is set apart from BD in this population by reduced allelic balance on 9p21-22 and reduced p16 expression, suggesting different paths of carcinogenesis for AK and BD in OTRs.
Drug-induced immunosuppression in OTRs dramatically increases the incidence of SCC by 60- to 100-fold.35 Immunosuppressants also act directly on keratinocytes,1 some on the transcriptional level, such as cyclosporine on ATF3,36 and some on the genomic level, such as azathioprine in conjunction with UV-A.20 Blokx and colleagues16 assessed p16 and p53 protein expression in 23 AK (low-grade KIN), 28 BD (high-grade KIN), and 35 invasive SCC cases from 44 OTRs and 42 immunocompetent control participants and concluded that p16 expression was independent of immune status and p53 expression. The present study showed that invasive SCC in OTRs exhibits reduced allelic balance for D9S162, but in contrast to intraepithelial SCC, p16 expression seems to be increased in SCC of OTRs compared with SCC of the general immunocompetent population.
Nilsson et al15 found weak and cytoplasmic p16INK4 expression in AK, strong nuclear and cytoplasmic p16INK4 expression in carcinomas in situ (BD), and variable p16INK4 expression in invasive SCC. Although the allelic balance in OTRs seems reduced for all samples at 9p21-22, in particular for OTR, the upregulation of p16 expression in SCC of OTRs is at this time difficult to interpret and suggests that a lack of p16 protein expression is not a factor in OTRs; rather, other mechanisms are involved in enhanced cutaneous squamous cell carcinogenesis. The data presented herein on the low correlation of allelic balance at 9p21-22 and tumor suppressor protein p16 and p53 expression underlines this difficulty. We conclude that SCC of OTRs, both intraepithelial and invasive, usually shows a reduced allelic balance on 9p21-22 compared with SCC in the general population. The expression of p16 seems to not be affected by such allelic imbalance at 9p21-22.
In summary, allelic balance at 9p21-22 is broadly reduced in all SCC, and OTRs have an even further reduced allelic balance for D9S162, suggesting a common trait for SCC in OTRs. Actinic keratosis and BD differ in allelic balance at D9S162, in particular among OTRs, suggesting essential differences in their carcinogenesis. Tumor suppressor protein p16, while located close to the observed reduced allelic balance, shows no close relationship to the allelic balance observed, nor does p53 have an effect.
The allelic imbalances found in our study suggest a role for them in the increased incidence and more aggressive carcinogenesis of SCC in OTRs. Our results add to the rationale for close clinical monitoring of OTRs to recognize and treat intraepithelial SCC early, preferably addressing field cancerization.
Correspondence: Günther F. L. Hofbauer, MD, Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, DERM E22, 8091 Zurich, Switzerland (firstname.lastname@example.org).
Accepted for Publication: January 14, 2012.
Published Online: April 16, 2012. doi:10.1001/archdermatol.2012.107
Author Contributions: Drs Mühleisen and Hofbauer had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Mühleisen and Hofbauer. Acquisition of data: Mühleisen, Petrov, Frigerio, and Hofbauer. Analysis and interpretation of data: Mühleisen, Frigerio, Dziunycz, French, and Hofbauer. Drafting of the manuscript: Mühleisen, Petrov, and Hofbauer. Critical revision of the manuscript for important intellectual content: Frigerio, Dziunycz, French, and Hofbauer. Obtained funding: Hofbauer. Administrative, technical, and material support: Mühleisen, Petrov, Frigerio, and Dziunycz. Study supervision: French and Hofbauer.
Financial Disclosure: None reported.
Funding/Support: This study was supported in part by the Baugarten Foundation, Zurich, Switzerland.
Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: Christa Dudli, MSc, Barbara Fruet, MSc, and the dermatohistopathology team lent their technical skill and expertise to this project, and Valentin Rousson, PhD, Department of Biostatistics, Institute for Social and Preventive Medicine, University of Zurich, Switzerland, provided statistical advice. Mss Dudli and Fruet and Dr Rousson received no financial compensation for their services.